Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
24.54
-0.04 (-0.16%)
At close: Jul 24, 2026, 4:00 PM EDT
24.53
-0.01 (-0.04%)
After-hours: Jul 24, 2026, 7:58 PM EDT
Pfizer Employees
Pfizer had 75,000 employees as of December 31, 2025. The number of employees decreased by 6,000 or -7.41% compared to the previous year.
Employees
75,000
Change (1Y)
-6,000
Growth (1Y)
-7.41%
Revenue / Employee
$844,200
Profits / Employee
$99,880
Market Cap
139.86B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,000 | -6,000 | -7.41% |
| Dec 31, 2024 | 81,000 | -7,000 | -7.95% |
| Dec 31, 2023 | 88,000 | 5,000 | 6.02% |
| Dec 31, 2022 | 83,000 | 4,000 | 5.06% |
| Dec 31, 2021 | 79,000 | 500 | 0.64% |
| Dec 31, 2020 | 78,500 | -9,800 | -11.10% |
| Dec 31, 2019 | 88,300 | -4,100 | -4.44% |
| Dec 31, 2018 | 92,400 | 2,200 | 2.44% |
| Dec 31, 2017 | 90,200 | -6,300 | -6.53% |
| Dec 31, 2016 | 96,500 | -1,400 | -1.43% |
| Dec 31, 2015 | 97,900 | 19,600 | 25.03% |
| Dec 31, 2014 | 78,300 | 600 | 0.77% |
| Dec 31, 2013 | 77,700 | -13,800 | -15.08% |
| Dec 31, 2012 | 91,500 | -12,200 | -11.76% |
| Dec 31, 2011 | 103,700 | -6,900 | -6.24% |
| Dec 31, 2010 | 110,600 | -5,900 | -5.06% |
| Dec 31, 2009 | 116,500 | 34,700 | 42.42% |
| Dec 31, 2008 | 81,800 | -4,800 | -5.54% |
| Dec 31, 2007 | 86,600 | -11,400 | -11.63% |
| Dec 31, 2006 | 98,000 | -8,000 | -7.55% |
| Dec 31, 2005 | 106,000 | -9,000 | -7.83% |
| Dec 31, 2004 | 115,000 | -7,000 | -5.74% |
| Dec 31, 2003 | 122,000 | 24,000 | 24.49% |
| Dec 31, 2002 | 98,000 | 8,000 | 8.89% |
| Dec 31, 2001 | 90,000 | 0 | - |
| Dec 31, 2000 | 90,000 | 39,100 | 76.82% |
| Dec 31, 1999 | 50,900 | 4,500 | 9.70% |
| Dec 31, 1998 | 46,400 | -2,800 | -5.69% |
| Dec 31, 1997 | 49,200 | 2,700 | 5.81% |
| Dec 31, 1996 | 46,500 | 2,700 | 6.16% |
| Dec 31, 1995 | 43,800 | 3,000 | 7.35% |
| Dec 31, 1994 | 40,800 | 300 | 0.74% |
| Dec 31, 1993 | 40,500 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| AbbVie | 57,000 |
PFE News
- 2 days ago - Pfizer's prostate cancer drug combination gets US FDA priority review - Reuters
- 2 days ago - FDA grants priority review for Pfizer’s Talzena plus Xtandi - TheFly
- 2 days ago - FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer - Business Wire
- 3 days ago - Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later - Reuters
- 8 days ago - Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - Reuters
- 8 days ago - Arbutus initiates patent infringement actions against Pfizer, BioNTech - TheFly
- 11 days ago - Pfizer price target lowered to $30 from $34 at BMO Capital - TheFly
- 11 days ago - Pfizer price target lowered to $35 from $36 at Guggenheim - TheFly